Navigation Links
Structural Genomics Consortium and CHDI Foundation announce new partnership
Date:6/5/2014

Toronto, Canada & New York City, USA; June 5, 2014 - The Structural Genomics Consortium (SGC) and CHDI Foundation have entered into a unique open-access research collaboration to discover and characterize new drug targets for Huntington's disease (HD) using structural and chemical biology In this first partnership of its kind, SGC and CHDI have explicitly agreed not to file for patents on any of the collaborative research and to make all reagents and knowledge available without restriction to the wider research community, including pharmaceutical, biotech, and academic research groups.

The SGC is a public-private partnership accelerating discovery of new drugs through an open-access research approach, with particular focus on neglected areas of the human genome, creating an open collaborative network of scientists in hundreds of universities and in nine major pharmaceutical companies. The collaboration with CHDIa not-for-profit drug development organization with a mission to rapidly develop drugs that will slow the progression of HDfurther focuses this approach within a specific disease domain. As part of the collaboration, CHDI will support scientists at the SGC to generate research tools to solve protein structures of potential drug targets for HD.

"This is a pioneering move by CHDI, and a template for how patient-orientated funders can help the research community develop new drugs," said Aled Edwards, CEO of the SGC. "With this collaboration the SGC is now pushing our open-access research to exploit specific chemical probes and define protein structures in a particular disease, in order to further clarify the underlying disease biology and aid drug discoverers in academia, biotech and pharma with the highest quality information about new drug targets."

The SGC will make any research tools developed freely available to the research community immediately and without restriction; working with a disease foundation will enable a targeted dissemination and rapid uptake of the developed research tools within the specific disease field.

"Ours is a knowledge-driven industry. By providing open access to their discoveries, the SGC and CHDI are doing exactly what is needed to help us discover and develop new medicines," said Tetsuyuki Maruyama, Head of Research at Takeda Pharmaceuticals. "This targeted approach within a specific disease domain will invite pharmaceutical sector researchers to look more closely at Huntington's disease as a tractable neurodegenerative disorder."

Since no patent protection on the results of this collaboration will be sought, any investigator will have complete freedom to operate. As part of the collaboration CHDI will facilitate the dissemination of SGC's existing novel inhibitors of epigenetics pathways into its network of scientists and clinicians to uncover potential new therapeutic targets for HD.

"We often refer to CHDI as a collaborative enabler with the aim of stimulating drug discovery research in Huntington's disease," said Robi Blumenstein, President of CHDI Management. "CHDI has long operated under the principle that the underlying disease biology should be freely accessible in a pre-competitive manner. This collaboration with the SGC will expand that pre-competitive domain to include biological structures, chemical probes and associated research data. Our aim is to ensure the HD research community has access to the best possible reagents and tools and that findings are made available rapidly and with the fewest restrictions to attract as many researchers as possible to work on HD. The ultimate goal is to get effective drugs to patients in the shortest possible time".


'/>"/>

Contact: Arij Al Chawaf
arij.alchawaf@thesgc.org
416-854-2745
University of Toronto
Source:Eurekalert

Related biology news :

1. OU research group awarded $9.7 million NIH CoBRE grant in structural biology
2. BBSRC and MRC renew investment in structural biology software
3. Price Family Foundation gift will create groundbreaking structural biology institute
4. Novel sensor system would flag structural weaknesses before bridges and stadiums collapse
5. SDSCs big data expertise aiding genomics research
6. BGI, University of Helsinki and Wuhan University sign a MOU concerning cooperation on genomics
7. In search for a vaccine, IU biologist receives $2.3 million to explore chlamydia genomics
8. ACRG and BGI report findings from genomics research on recurrent hepatitis B virus integration
9. The genomics symposium to boost the further development of cancer research
10. Elsevier launches new open access journal: Applied and Translational Genomics
11. ShanghaiBio Corporation Partners with Ingenuity Systems to Address Challenges in Analysis and Interpretation of Genomics Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... With the biometrics market to exceed ... technologies that innovative and agile startups must incorporate ... the changing competitive landscape: multifactor authentication (MFA), point-of-sale ... "Companies can no longer afford to cut ... Dimitrios Pavlakis , Industry Analyst at ABI Research. ...
(Date:2/21/2017)... Ore. , Feb. 22, 2017  IBM (NYSE: ... (Avamere Health Services, Infinity Rehab, Signature Hospice, Home Health, ... will apply the power of IBM cognitive computing to ... centers. By analyzing data streaming from sensors in senior ... and environmental conditions, and obtain deeper learnings into the ...
(Date:2/21/2017)... 21, 2017 Der weltweite Biobanking-Sektor ... Nach einem Gespräch mit mehr als 50 Vertretern aus verschiedenen ... überwinden gilt, um diese Prognose zu realisieren. ... Zu ... der finanziellen Mittel für die Biobank, die Implementierung Zeit ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... 22, 2017 Scientists propose in Nature ... damage in Gaucher and maybe other lysosomal storage diseases ... costs than current therapies. An international research ... , which also included investigators from the University of ... data Feb. 22. The study was conducted in mouse ...
(Date:2/22/2017)... Dublin - Research and Markets has announced ... Type, By Application, By End User, By Region, By Country: Opportunities ... ... is forecasted to grow at a CAGR of 11.33% during 2016-2021. ... protection market is driven by the surging demand for less toxic ...
(Date:2/22/2017)... DIEGO , Feb. 22, 2017  Creative ... expansion of its translational research program using its ... of laboratory facilities in San Diego.  The Company ... BioLabs facility, a biotechnology incubator sponsored by the ... In November 2016, the Company obtained an ...
(Date:2/21/2017)... , ... February 21, 2017 , ... ... VTX-1 Liquid Biopsy System , a fully automated benchtop system for collecting intact ... VTX-1 is being launched at the Molecular Medicine Tri Conference (Tri-Con) Annual Meeting ...
Breaking Biology Technology: